InvestorsHub Logo
Followers 594
Posts 20577
Boards Moderated 0
Alias Born 02/01/2012

Re: None

Tuesday, 03/21/2017 11:32:09 AM

Tuesday, March 21, 2017 11:32:09 AM

Post# of 34575
$TPIV The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $3.7 million to conduct a Phase 2 trial of TapImmune’s HER21-targeted T-cell vaccine in women with the breast cancer known as ductal carcinoma in situ (DCIS).

https://breastcancer-news.com/2017/03/20/us-department-of-defense-funds-phase-2-trial-of-breast-cancer-vaccine/

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News